T. Rowe Price Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

T. Rowe Price Associates’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,087,776	Closed	-$274M	–	2620
2017 Q4	$274M	Buy	5,087,776 +1,300,396	+34%	+$71.2M	0.04%	388
2017 Q3	$216M	Buy	3,787,380 +1,294,586	+52%	+$75.8M	0.04%	437
2017 Q2	$150M	Buy	2,492,794 +1,186,806	+91%	+$67.6M	0.03%	502
2017 Q1	$71.1M	Buy	+1,305,988	New	+$64.3M	0.01%	692

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

T. Rowe Price Associates's BIVV Position: Q1 2018 in Review

T. Rowe Price Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 5,087,776 shares — an estimated $274M sold.

T. Rowe Price Associates first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $274M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

T. Rowe Price Associates reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
T. Rowe Price Associates sold 5,087,776 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $274M.
T. Rowe Price Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
T. Rowe Price Associates's Bioverativ Inc. Common Stock position peaked at $274M in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on T. Rowe Price Associates's 13F filing for Q1 2018, filed 14 May 2018.